What are 2x ETFs for Novo Nordisk to invest?

``` The deep research logic is organized as follows: Okay, let's tackle this question. The user is asking about 2x ETFs for Novo Nordisk. First, I need to check the references provided. Looking at Reference 1, there's an ETF called Defiance Daily Target 2X Long NVO ETF with the code NVOX.P. It's the only one listed, so that's the main candidate. The leverage ratio is 2, which fits the user's request for 2x ETFs. Next, I should look at the performance data. Reference 10 shows the historical performance of NVOX.P over different periods. The 1-month performance is -42.9%, 3-month is -40%, and 6-month is -69.83%. That's pretty steep declines, which might be concerning for the user. Now, considering the user's profile, they're interested in the NAS Composite Index, which is a broad market index. The user might be looking for ETFs that offer leveraged exposure to a specific stock within the context of the broader market. However, NVOX.P is a single-stock ETF, so it's more concentrated risk. Also, there are several legal issues mentioned in References 2-5, 7, 8, and 11. These include class action lawsuits related to securities fraud, patent disputes, and regulatory scrutiny. These factors could impact Novo Nordisk's stock price and, by extension, the ETF's performance. The user should be aware of these risks. The user might be considering leveraged ETFs for speculative purposes or to hedge their NAS Composite exposure. However, given the high volatility and legal risks, the ETF might not align well with a broad market strategy. The performance data shows significant losses, which could be a red flag. I should structure the answer by first stating the available ETF, then discussing its performance, followed by the legal and market risks. Also, since the user prefers the NAS Composite, I should mention that this ETF is a single-stock play and not part of the broader index. Make sure to include the visualization for the ETF's performance as per the query in Reference 10. Also, cite all relevant references properly. The conclusion should highlight the high risk and potential unsuitability for the user's broad market focus. ``` ### Conclusion 🚨 **There is only one 2x leveraged ETF available for Novo Nordisk (NVO.N) as of August 25, 2025: the Defiance Daily Target 2X Long NVO ETF (NVOX.P)**. However, this ETF carries significant risks due to its concentrated exposure to Novo Nordisk, recent stock price volatility, and ongoing legal challenges . Below is a detailed analysis of this ETF and its suitability for investors. --- ### 1. **Available 2x Leveraged ETF for Novo Nordisk** The only ETF tracking Novo Nordisk with a 2x leverage ratio is: | ETF Code | ETF Name | Last Price | Last Change | Leverage Ratio | |----------|----------|------------|-------------|----------------| | NVOX.P | Defiance Daily Target 2X Long NVO ETF | $3.78 | -1.44% | 2x | This ETF aims to deliver **2x daily returns** of Novo Nordisk’s stock price. However, its performance over recent periods has been highly volatile: | Period | Performance | |--------------|-------------| | 1-month (Jul 25–Aug 25, 2025) | -42.9% | | 3-month (May 23–Aug 25, 2025) | -40.0% | | 6-month (Feb 26–Aug 25, 2025) | -69.83% | |code|Ticker|Name|Date|Closing Price|market_code| |---|---|---|---|---|---| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250725|6.76|169| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250728|6.22|169| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250729|3.54|169| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250730|3.02|169| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250731|2.64|169| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250801|2.75|169| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250804|2.83|169| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250805|2.65|169| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250806|2.45|169| |NVOX|NVOX.P|Defiance Daily Target 2X Long NVO ETF|20250807|2.8|169| --- ### 2. **Key Risks and Market Context** #### a) **Legal and Regulatory Risks** Novo Nordisk is facing **multiple class action lawsuits** alleging securities fraud, misrepresentation of growth prospects, and failure to disclose risks related to competition from compounded GLP-1 drugs and Eli Lilly’s products . These lawsuits stem from the company’s **21.83% stock price drop** on July 29, 2025, after cutting its 2025 sales outlook due to slower market expansion and regulatory headwinds . #### b) **Market Competition** The GLP-1 market is becoming increasingly competitive, with **Eli Lilly’s Zepbound** and **Indian generics** (e.g., Natco Pharma’s semaglutide) posing direct threats to Novo Nordisk’s dominance . Additionally, regulatory scrutiny over pricing and patient access could further pressure the company’s margins . #### c) **Concentrated Risk** As a single-stock ETF, NVOX.P lacks diversification, making it highly sensitive to Novo Nordisk’s stock-specific risks. This contrasts with the user’s interest in the NAS Composite Index, which offers broad market exposure . --- ### 3. **Why This ETF Might Not Be Ideal for You** - **High Volatility**: The ETF’s 6-month performance (-69.83%) reflects extreme price swings, which could amplify losses due to the 2x leverage . - **Legal Uncertainty**: Ongoing lawsuits and regulatory challenges could further destabilize Novo Nordisk’s stock price . - **Misalignment with NAS Composite Focus**: This ETF focuses on a single stock, whereas the NAS Composite Index represents a diversified portfolio of U.S. equities . --- ### 4. **Conclusion for Investors** While NVOX.P provides **2x leveraged exposure** to Novo Nordisk, it comes with **high risk** due to legal, competitive, and market volatility factors. For investors prioritizing broad market exposure (as indicated by your interest in the NAS Composite Index), this ETF may not align with your goals. Consider exploring **diversified ETFs** or **index funds** instead. Let me know if you’d like further analysis on alternative investment strategies! 🚀